

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Sep 2026

Efficacy of combination therapy of L-glutamine and Hydroxyurea in comparison with Hydroxyurea alone in patients with sickle cell anemia: a randomized, double-blinded clinical trial

Protocol summary

Study aim

Comparison of combination therapy of L-glutamine and hydroxyurea compared with hydroxyurea alone in patients with sickle cell anemia

Design

The final sample size is 126 people in total (63 people in each group) This study is a randomized, controlled, parallel clinical trial in which all patients are examined in two groups. Intervention group A will receive L-glutamine and hydroxyurea combination therapy, and group B will receive hydroxyurea treatment alone (control group).

Settings and conduct

This study is a randomized, controlled trial (standard treatment of hydroxyurea), double-blind and 6-month parallel group. The allocation of two randomized block blinds is encoded in numbered envelopes and is prepared according to the sample size and will be provided to the patient's attending physician.

Participants/Inclusion and exclusion criteria

Patients who are at least 5 years old; diagnosed with sickle cell anemia, and have documented at least two pain crises in the past year are eligible to enter the study. Patients who receive hydroxyurea treatment at a dose that is constant for at least 3 months prior to screening and intend to continue that treatment are eligible to participate. Exclusion criteria are: Patients admitted for non-sickle cell disease within 2 months prior to screening, normalized international prothrombin time ratio greater than 2.0, serum albumin level less than 3.0 g / dL, Each blood product is taken 3 weeks before screening and has clinically significant kidney or liver disease, treated with L-glutamine within 30 days before screening.

Intervention groups

Receive a combination of L-glutamine and hydroxyurea

Main outcome variables

The main outcome variable of the study is the number of

pain crises at the end of 6 months.

General information

Reason for update

I would like to designate the acronym "GLOBE Trial" (Glutamine and Hydroxyurea Benefit Evaluation in Sickle Cell Anemia) for this study.

Acronym

GLOBE Trial

IRCT registration information

IRCT registration number: **IRCT20210715051904N1**

Registration date: **2022-02-19, 1400/11/30**

Registration timing: **registered_while_recruiting**

Last update: **2025-08-04, 1404/05/13**

Update count: **1**

Registration date

2022-02-19, 1400/11/30

Registrant information

Name

Nader Shakibazad

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 77 3335 1048

Email address

shakibn@bpums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-02-14, 1400/11/25

Expected recruitment end date

2022-10-17, 1401/07/25

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Efficacy of combination therapy of L-glutamine and Hydroxyurea in comparison with Hydroxyurea alone in patients with sickle cell anemia: a randomized, double-blinded clinical trial

Public title

The effect of combination therapy of L-glutamine and hydroxyurea in patients with sickle cell anemia

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Patients with sickle-cell syndrome Age more than five-year-old No other accompanying hematologic diseases All patients should be on Hydroxyurea At least two (extreme) pain crises have been documented in the past year (defining a pain crisis as pain that results from treatment with a drug or injectable ketorolac in the emergency department (ED) (or outpatient treatment center) or during hospitalization. Becomes)

Exclusion criteria:

Occurrence of life-threatening events not related to SCD during treatment Patient dissatisfaction with participation in the study Serum albumin levels are less than 3 g / dL Internationally normalized ratios of prothrombin time are higher than 2.0 The treated with L-glutamine within 30 days prior to screening.

AgeFrom **5 years** old**Gender**

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample sizeTarget sample size: **126****Randomization (investigator's opinion)**

Randomized

Randomization description

This study is a randomized controlled clinical trial in which all patients are examined in two groups, which we represent with two symbols A and B. Group A will receive L-glutamine and hydroxyurea combination therapy in the intervention (intervention group) and group B will receive hydroxyurea treatment alone (control group). Participants in the study will be randomly divided into two groups A and B equal to individual. In order to randomly assign individuals to two equal groups to

receive the intervention, the Permuted Block Randomization method with a block size of 6 has been used. The block randomization scheme was created using the free Randomization.com website (<http://randomization.com>). From the order of the Permuted Block Randomization table, the allocator and evaluator should not be aware of the type of intervention being performed on the individual and the size of the block. Thus, it can be said that the data allocation will remain hidden until the end of the study. Thus, each participant will be assigned to intervention or control groups and will enter the study. 1.

A	2.
A	3.
B	4.
B	5.
B	6.
A	7.
A	8.
B	9.
B	10.
A	11.
B	12.
A	13.
A	14.
B	15.
B	16.
A	17.
A	18.
B	19.
A	20.
B	21.
B	22.
A	23.
A	24.
B	25.
B	26.
A	27.
A	28.
B	29.
B	30.
A	31.
A	32.
A	33.
B	34.
B	35.
B	36.
A	37.
A	38.
B	39.
B	40.
A	41.
B	42.
A	43.
A	44.
B	45.
B	46.
A	47.
A	48.
B	49.
A	50.
B	51.

B	52.
A	53.
A	54.
B	55.
B	56.
A	57.
A	58.
B	59.
B	60.
A	61.
A	62.
A	63.
B	64.
B	65.
B	66.
A	67.
A	68.
B	69.
B	70.
A	71.
B	72.
A	73.
A	74.
B	75.
B	76.
A	77.
A	78.
B	79.
A	80.
B	81.
B	82.
A	83.
A	84.
B	85.
B	86.
A	87.
A	88.
B	89.
B	90.
A	91.
A	92.
A	93.
B	94.
B	95.
B	96.
A	97.
A	98.
B	99.
B	100.
A	101.
B	102.
A	103.
A	104.
B	105.
B	106.
A	107.
A	108.
B	109.
A	110.
B	111.
B	112.
A	113.

A	114.
B	115.
A	116.
A	117.
B	118.
B	119.
B	120.
A	121.
A	122.
B	123.
B	124.
A	125.
B	126.
A	

Blinding (investigator's opinion)

Double blinded

Blinding description

From the order of the Permuted Block Randomization table, the allocator and evaluator should not be aware of the type of intervention being performed on the individual and the size of the block. Thus, it can be said that the data allocation will remain hidden until the end of the study. In this way, each participant will be assigned to intervention or control groups and will be included in the study. Pain Crisis Judgment and Laboratory Tests: All pain crises reported in the case report forms will be recorded by the researchers. An independent judging panel consisting of two hematologists-oncologists who are unaware of the assignment of the trial team will evaluate each episode to determine whether the event meets the definition of a pain crisis for performance evaluation.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Research Ethics Committees of Bushehr province university of medical sciences

Street address

BPUMS Vice chancellery for Education, Bushehr University of Medical Sciences, Salman Farsi St, Alamdar St, Bushehr, Iran.

City

Boushehr

Province

Boushehr

Postal code

7518759577

Approval date

2021-09-19, 1400/06/28

Ethics committee reference number

IR.BPUMS.REC.1400.107

Health conditions studied

1

Description of health condition studied

Sickle cell anemia, L-glutamine, hydroxyurea, pain crisis

ICD-10 code

D57

ICD-10 code description

Sickle-cell disorders, Sickle-cell anaemia with crisis, Sickle-cell anaemia without crisis, Double heterozygous sickling disorders, Sickle-cell trait, Other sickle-cell disorders

Primary outcomes

1

Description

Number of pain crisis

Timepoint

Before intervention and 6 months after intervention

Method of measurement

Clinical examination by a pediatric hematologist and oncologist

2

Description

Number of hospitalizations for pain associated with sickle cell anemia

Timepoint

Before intervention and 6 months after intervention

Method of measurement

Clinical examination by a pediatric hematologist and oncologist

Secondary outcomes

1

Description

Number of Priapism event

Timepoint

Before intervention and 6 months after intervention

Method of measurement

Clinical examination by a pediatric hematologist and oncologist

2

Description

Number of acute chest syndrome

Timepoint

Before intervention and 6 months after intervention

Method of measurement

Clinical examination by a pediatric hematologist and oncologist

3

Description

Number of splenic sequestration events

Timepoint

Before intervention and 6 months after intervention

Method of measurement

Clinical examination by a pediatric hematologist and oncologist

Intervention groups

1

Description

Intervention group: Intervention group: The allocation of two randomized block blinds is encoded in numbered envelopes and is prepared according to the number of samples and will be provided to the patient's attending physician. Therefore, eligible patients will be randomly divided into a 1: 1 ratio for L-glutamine and hydroxyurea combination therapy or hydroxyurea alone, with randomized block allocation. The planned treatment period will be 6 months, during which patients, in addition to consuming hydroxyurea, take L-glutamine powder orally twice a day at a dose of approximately 0.3 g / kg body weight per dose (10 g, 20 g). Grams or 30 grams [maximum dose] per day). The contents of the package will be mixed with an unheated drink or food and consumed immediately. Patients will be contacted by telephone each week between monthly visits to encourage adherence. The validity of the test group assignment and the correct supply of L-glutamine or placebo for each patient will be verified by an independent research drug service. Patients can receive blood transfusions and other necessary clinical treatments if needed.

Category

Treatment - Drugs

2

Description

Control group: The allocation of two randomized block blinds is encoded in numbered envelopes and is prepared according to the number of samples and will be provided to the patient's attending physician. Therefore, eligible patients will be randomly divided into a 1: 1 ratio for L-glutamine and hydroxyurea combination therapy or hydroxyurea alone, with randomized block allocation. The planned treatment period will be 6 months, during which the control group will receive placebo powder (100% maltodextrin) orally twice a day. Experimental drug and placebo in individual packages and visually identical contain 5 grams of white powder without taste is provided, and all packages will be returned by patients to assess compliance. The contents of the package will be mixed with an unheated drink or food and consumed immediately. Patients will be contacted by telephone each week between monthly visits to encourage adherence. The validity of the test group assignment and the correct supply of L-glutamine or placebo for each patient will be verified by an independent research drug

service. Patients can receive blood transfusions and other necessary clinical treatments if needed.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shohadaye Khalij-e-fars hospital

Full name of responsible person

Nader Shakibazad

Street address

Ayatollah Taleghani Boulevard, Shohadaye Khalij-e-fars hospital

City

Boushehr

Province

Boushehr

Postal code

7517933755

Phone

+98 77 3345 5375

Email

mpgh@bpums.ac.ir

2

Recruitment center

Name of recruitment center

Dr.shakibazad pediatric oncology clinic

Full name of responsible person

Nader Shakibazad

Street address

Tabib medical building (9th floor), Keshtirani crossroads, boushehr, Iran

City

Boushehr

Province

Boushehr

Postal code

7514799621

Phone

+98 77 3335 1048

Email

shakibazadnader@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Boushehr University of Medical Sciences

Full name of responsible person

GHolamreza Khamisipour

Street address

BPUMS Vice chancellery for Research, Bushehr University of Medical Sciences, Salman Farsi St, Alamdar St, Bushehr, Iran.

City

boushehr

Province

Boushehr

Postal code

7518759577

Phone

+98 77 3345 0178

Email

research@bpums.ac.ir

Grant name

Vice Chancellor for Research, Bushehr University of Medical Sciences

Grant code / Reference number

1755

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Boushehr University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Boushehr University of Medical Sciences

Full name of responsible person

Nader Shakibazad

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatric hematology and oncology

Street address

Tabib Medical Building (9th floor), Keshtirani crossroads, Boushehr, Iran

City

Boushehr

Province

Boushehr

Postal code

7514799621

Phone

+98 77 3335 1048

Email

shakibn@bpums.ac.ir

Person responsible for scientific

inquiries

Contact

Name of organization / entity

Boushehr University of Medical Sciences

Full name of responsible person

Nader Shakibazad

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatric hematology and oncology

Street address

Tabib medical building (9th floor), Keshtirani
crossroads, boushehr, Iran

City

Boushehr

Province

Boushehr

Postal code

7514799621

Phone

+98 77 3335 1048

Email

shakibn@bpums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Boushehr University of Medical Sciences

Full name of responsible person

Nader Shakibazad

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

pediatric hematology and oncology

Street address

Tabib Medical Building (9th floor), Keshtirani
crossroads, Boushehr, Iran City Boushehr Province
Boushehr

City

Boushehr

Province

Boushehr

Postal code

7514799621

Phone

+98 77 3335 1048

Email

shakibn@bpums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to
make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to
make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to
make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to
make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to
make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable